5-[[(2R)-2-[(1S)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2H-furan-3-yl]oxy]-5-oxopentanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 5-[[(2R)-2-[(1S)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2H-furan-3-yl]oxy]-5-oxopentanoic acid
• 化学式: C₁₁H₁₄O₉
• 分子量: 290.22
• InChiKey: OWRHMMWZGMVNAY-SSDLBLMSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  20
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  151
• 氢给体数：
  4
• 氢受体数：
  9

文献信息

• [EN] INHIBITORS OF BRUTON'S TYROSINE KINASE<br/>[FR] INHIBITEUR DE TYROSINE KINASE DE BRUTON
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014083026A1

  公开（公告）日：2014-06-05

  This application discloses the Btk inhibitor compounds 6-tert-Butyl-8-fluoro-2-3- hydroxymethyl-4-[1-methyl-5-(1'-methyl-1',2',3',4',5',6'-hexahydro-[3,4']bipyridinyl-6-ylamino)- 6-oxo-1,6-dihydro-pyridazin-3-yl]-pyridin-2-yl}-2H-phthalazin-1-one, 2-(2-3-[5-(5-Azetidin-1- ylmethyl-1-methyl-1H-pyrazol-3-ylamino)-1-methyl-6-oxo-1,6-dihydro-pyridazin-3-yl]-2- hydroxymethyl-phenyl}-8-fluoro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-methyl-propionitrile, and 6-tert-Butyl-2-[2-hydroxymethyl-3-(5-5-[(2-methoxy-ethylamino)-methyl]-pyridin-2- ylamino}-6-oxo-1,6-dihydro-pyridin-3-yl)-phenyl]-3,4-dihydro-2H-isoquinolin-1-one, formulations thereof, and methods of treatment of asthma, as described herein.

  该申请公开了Btk抑制剂化合物6-叔丁基-8-氟-2-3-羟甲基-4-[1-甲基-5-(1'-甲基-1',2',3',4',5',6'-六氢-[3,4']联氮基-6-基氨基)-6-氧代-1,6-二氢吡啶-3-基]-吡啶-2-基}-2H-菲噻嗪-1-酮，2-(2-3-[5-(5-氮杂环丙氨基-1-甲基-1H-吡唑-3-基氨基)-1-甲基-6-氧代-1,6-二氢吡啶-3-基]-2-羟甲基-苯基}-8-氟-1-氧代-1,2-二氢-异喹啉-6-基)-2-甲基-丙腈，以及6-叔丁基-2-[2-羟甲基-3-(5-5-[(2-甲氧基-乙基氨基)-甲基]-吡啶-2-基氨基}-6-氧代-1,6-二氢吡啶-3-基)-苯基]-3,4-二氢-2H-异喹啉-1-酮，其配方以及治疗哮喘的方法，如本文所述。
• INHIBITORS OF BRUTON'S TYROSINE KINASE
  申请人：HOFFMANN-LA ROCHE INC.

  公开号：US20150290192A1

  公开（公告）日：2015-10-15

  This application discloses the Btk inhibitor compounds 6-tert-Butyl-8-fluoro-2-3-hydroxymethyl-4-[1-methyl-5-(1′-methyl-1′,2′,3′,4′,5′,6′-hexahydro-[3,4′]bipyridinyl-6-ylamino)-6-oxo-1,6-dihydro-pyridazin-3-yl]-pyridin-2-yl}-2H-phthalazin-1-one, 2-(2-3-[5-(5-Azetidin-1-ylmethyl-1-methyl-1H-pyrazol-3-ylamino)-1-methyl-6-oxo-1,6-dihydro-pyridazin-3-yl]-2-hydroxy methyl-phenyl}-8-fluoro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-methyl-propionitrile, and 6-tert-Butyl-2-[2-hydroxymethyl-3-(5-5-[(2-methoxy-ethylamino)-methyl]-pyridin-2-ylamino}-6-oxo-1,6-dihydro-pyridin-3-yl)-phenyl]-3,4-dihydro-2H-isoquinolin-1-one, formulations thereof, and methods of treatment of asthma, as described herein.

  本申请披露了Btk抑制剂化合物6-叔丁基-8-氟-2-3-羟甲基-4-[1-甲基-5-(1'-甲基-1',2',3',4',5',6'-六氢-[3,4']联吡啶-6-基氨基)-6-氧代-1,6-二氢-吡啶并[3,4']嘧啶-3-基]-吡啶-2-基}-2H-邻菲啉-1-酮，2-(2-3-[5-(5-氮杂环己烷-1-甲基-1-甲基-1H-吡唑-3-基氨基)-1-甲基-6-氧代-1,6-二氢-吡啶并[3,4']嘧啶-3-基]-2-羟甲基-苯基}-8-氟-1-氧代-1,2-二氢-异喹啉-6-基)-2-甲基-丙腈，以及6-叔丁基-2-[2-羟甲基-3-(5-5-[(2-甲氧基乙基)氨基甲基]-吡啶-2-基氨基}-6-氧代-1,6-二氢-吡啶-3-基)-苯基]-3,4-二氢-2H-异喹啉-1-酮，其制剂和治疗哮喘的方法，如本文所述。